Menu

Filters

  • Result Found In

Flu Vaccine NOW AVAILABLE
BD Veritor System

BD Veritor System

BD Diagnostics Systems -Henry Schein

BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves health care institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. For more information, please visit www.bd.com.

BD Featured Products

The BD Veritor™ Plus system provides objective, lab-quality immunoassay test results for healthcare providers and laboratorians in physician offices, clinics, hospitals and IDNs—within minutes. The system streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. It can also help detect infectious diseases such as influenza A and B, respiratory syncytial virus (RSV) and group A strep while the patient is still on site, which may facilitate decision making for earlier intervention.


BD Veritor™ Plus System

The new wireless BD Veritor™ Plus System provides lab-quality immunoassay test results within minutes. This fast and accurate solution streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. BD Veritor™ Plus System can help detect infectious diseases, such as influenza A and B, respiratory syncytial virus (RSV), and group A strep while the patient is still on site, which can enable faster decision-making for an earlier intervention opportunity.

  • Faster access to test results: Help inform appropriate and targeted treatment decisions
  • Improved workflow: The BD Veritor™Plus Analyzer improves workflow with an Analyze Now or Walk Away mode, providing test results (with a print-enabled function) and aiding in decision-making while the patient is on site
  • Improved traceability: The BD Veritor™ InfoScan module can scan 3 different identifiers (operator ID, specimen ID, and test kit/lot) that can be locally recorded, printed, or downloaded, and reduces hands-on time through automated documentation
  • Modularity: Provides a unique solution to meet each testing site's preference Connectivity: BD Veritor™ InfoSync module provides the same benefits as BD Veritor™ InfoScan. Connects and documents tests results across multiple sites and can integrate with a hospital's electronic medical record or laboratory information system
  • Advanced particle technology: Enhances sensitivity by using a proprietary process to produce highly stable, modified colloidal metal particles.
  • Adaptive read technology: Compensates for background. Nonspecific binding helps improve specificity to reduce false positive results

Product Details and Ordering »

Veritorâ„¢ Plus System - Henry Schein


BD Veritor™ System Flu A+B Test Kit

The first CLIA-waived flu A+B test referenced against PCR, a higher sensitivity standard than culture. Device is ready to insert into reader 10 minutes after same is added.

  • Positive percent agreement (A/B): 82.1%/74.6
  • Negative percent agreement (A/B): 98.6%/99.6%
  • Positive agreement vs. PCR for current visual read rapid tests ranges from 10% to 70% Streamlined workflow: Provides a digital result in 11 minutes, with 50 seconds of hands-on time

Product Details and Ordering »

BD Veritorâ„¢ System Flu A+B Test Kit-Henry Schein